Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

21. Use of sacubitril/valsartan in acute decompensated heart failure: a case report Full Text available with Trip Pro

Use of sacubitril/valsartan in acute decompensated heart failure: a case report Refractory heart failure typically requires costly long-term, continuous intravenous inodilator infusions while patients await mechanical circulatory support or cardiac transplantation. The combined angiotensin receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. This therapy has been recommended as an alternative agent (...) in patients with chronic heart failure with reduced ejection fraction and New York Heart Association class II-III symptoms. Here, we report a case of a patient with refractory stage D heart failure with reduced ejection fraction who was successfully weaned off continuous intravenous inodilator support using sacubitril/valsartan after prior failed attempts using standard therapies.© 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2017 ESC heart failure

22. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients Full Text available with Trip Pro

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were (...) included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified

2017 International journal of chronic diseases

23. Entresto (sacubitril, valsartan) - treatment of heart failure

Entresto (sacubitril, valsartan) - treatment of heart failure Entresto (sacubitril, valsartan) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Entresto (sacubitril, valsartan) Conclusion Entresto is the first medicine in the class of combined angiotensin receptor neprilysin inhibitors (ARNI) containing valsartan and sacubitril. It is indicated for the treatment of heart failure as an alternative to angiotensin converting enzyme (ACE) inhibitors

2017 Danish Pharmacotherapy Reviews

24. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach Full Text available with Trip Pro

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach Sacubitril/Valsartan, proved superiority over other conventional heart failure management treatments, but its mechanisms of action remains obscure. In this study, we sought to explore the mechanistic details for Sacubitril/Valsartan in heart failure and post-myocardial infarction remodeling, using an in silico, systems biology approach. Myocardial transcriptome obtained in response to myocardial (...) a set of molecular criteria, defining both pathologies and including all the information available on Sacubitril/Valsartan, were generated. All relationships incorporated into the biological network were drawn from public resources (including KEGG, REACTOME, INTACT, BIOGRID, and MINT). An artificial neural network analysis revealed that Sacubitril/Valsartan acts synergistically against cardiomyocyte cell death and left ventricular extracellular matrix remodeling via eight principal synergistic nodes

2017 NPJ systems biology and applications

25. Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients

Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients Prescrire IN ENGLISH - Spotlight ''Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients'', 1 February 2017 {1} {1} {1} | | > > > Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients FEATURED REVIEW Replacing an ACE inhibitor or an ARB with the high-dose sacubitril + valsartan combination should be envisaged with care, and solely for heart failure patients comparable to those included in the only available trial. Most chronic heart failure patients should continue to use

2017 Prescrire

26. Sacubitril/valsartan - Addendum to Commission A15-60

Sacubitril/valsartan - Addendum to Commission A15-60 1 Translation of addendum A16-29 Sacubitril/Valsartan – Addendum zum Auftrag A15-60 (Version 1.0; Status: 25 May 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 May 2016 1.0 Commission: A16-29 Version: Status: IQWiG Reports – Commission No. A16-29 Sacubitril/valsartan – Addendum (...) to Commission A15-60 1 Addendum A16-29 Version 1.0 Sacubitril/valsartan (Addendum to Commission A15-60) 25 May 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sacubitril/valsartan – Addendum to Commission A15-60 Commissioning agency: Federal Joint Committee Commission awarded on: 10 May 2016 Internal Commission No.: A16-29 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

27. Efficacy of sacubitril / valsartan in the treatment of hypertension

Efficacy of sacubitril / valsartan in the treatment of hypertension Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2017 PROSPERO

28. ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex)

ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2017 Health Canada - Drug and Health Product Register

29. Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy

Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca July (...) 10, 2017 Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy Clinical Question: Is sacubitril/valsartan (Entresto®) effective for systolic heart failure (HF)? Bottom Line: Based on one randomized controlled trial (RCT), for every 36 patients with heart failure switched from ACE inhibitors to sacubitril/valsartan, one fewer will die and one fewer will be admitted for heart failure over 27 months. Beta-blockers and aldosterone antagonists should be offered first and continued

2017 Tools for Practice

30. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. (Abstract)

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin (...) -angiotensin-aldosterone system increases the risk of hyperkalemia.To determine whether the risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/valsartan in comparison with enalapril.The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40

2016 JAMA cardiology Controlled trial quality: uncertain

31. Sacubitril/valsartan - Benefit assessment

Sacubitril/valsartan - Benefit assessment Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sacubitril/Valsartan – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 March 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-60 Sacubitril/valsartan – Benefit assessment according to §35a Social (...) Code Book V 1 Extract of dossier assessment A15-60 Version 1.0 Sacubitril/valsartan – Benefit assessment acc. to §35a Social Code Book V 30 March 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sacubitril/valsartan – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 23 December 2015 Internal Commission No.: A15-60

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

32. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. (Abstract)

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction.To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure.Markov decision model.Clinical trials, observational analyses, reimbursement data (...) from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables.Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less.Lifetime.Societal.Treatment with sacubitril-valsartan or lisinopril.Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospitalizations, and incremental cost-effectiveness ratios.The

2016 Annals of Internal Medicine

33. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study Full Text available with Trip Pro

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia.The objective of this study

2016 Drugs - real world outcomes

34. [Sacubitril/valsartan: addendum to commission A15-60]

[Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29. [Sacubitril/valsartan: addendum to commission A15-60] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 394. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Tetrazoles; Valine; Valsartan Language Published

2016 Health Technology Assessment (HTA) Database.

35. Neparvis (sacubitril / valsartan) - heart failure

Neparvis (sacubitril / valsartan) - heart failure 1 April 2016 EMA/255018/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment Report Neparvis International non-proprietary name: sacubitril / valsartan Procedure No. EMEA/H/C/004343/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 (...) CLCZ696B2314 (also known as PARADIGM-HF) was designed to accomplish this purpose. LCZ696 (sacubitril/valsartan, Neparvis) is a novel therapy proposed for treatment of heart failure (HF) (New York Heart Association (NYHA) class II-IV) in patients with systolic dysfunction (reduced ejection fraction, HFrEF). Following oral administration, LCZ696 dissociates into valsartan and the pro-drug sacubitril (also known as AHU377, a new molecular entity), which is further metabolized to the neprilysin inhibitor

2016 European Medicines Agency - EPARs

36. [Sacubitril/valsartan - benefit assessment]

[Sacubitril/valsartan - benefit assessment] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60. [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 379. 2016

2016 Health Technology Assessment (HTA) Database.

37. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Sacubitril valsartan for treating Sacubitril valsartan for treating symptomatic chronic heart failure with symptomatic chronic heart failure with reduced ejection fr reduced ejection fraction action T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta388 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

38. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. (Abstract)

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which (...) was inadequately controlled by valsartan 80 mg/day.After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive either extended-release bunazosin (n = 47) or doxazosin (n = 46) after breakfast for 8 weeks. Office sitting blood pressure (BP), 24-hour ambulatory BP, and metabolic profiles were measured at baseline, start of study drug, and study end.In the intention-to-treat population (n = 93), the average daily doses of bunazosin

2016 Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica Controlled trial quality: uncertain

39. Amlodipine / Valsartan Mylan - hypertension

Amlodipine / Valsartan Mylan - hypertension 28 January 2016 EMA/CHMP/182030/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Amlodipine/Valsartan Mylan International non-proprietary name: amlodipine / valsartan Procedure No. EMEA/H/C/004037/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone (...) /National Formulary UV Ultraviolet light Assessment report EMA/CHMP/182030/2016 Page 4/31 1. Background information on the procedure 1.1. Submission of the dossier The applicant MYLAN S.A.S. submitted on 20 January 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Amlodipine/Valsartan Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the centralised

2016 European Medicines Agency - EPARs

40. LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips

LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips November 2015 LCZ696 (Sacubitril/Valsartan), Entresto TM Summary and Practical Tips Mechanism of action: sacubitril is a neprilysin (endopeptidase) inhibitor: ?vasodilatory peptides ? ?sodium loss, ?hypertrophy/remodeling. Combination with an ARB is necessary as inhibition of neprilysin leads to activation of the renin angiotensin aldosterone system (RAAS). Indication: • Health Canada Indication 1 : heart failure with reduced (...) ejection fraction (HFrEF), NYHA class II-III, in combination with other heart failure (HF) therapies in place of an ACEI or ARB • CCS HF 2014 Guidelines 2 : mild-moderate HF, left ventricular ejection fraction (LVEF) 5.2 mmol/L • History of angioedema Dosing: • Tablet: film-coated, unscored containing both sacubitril and valsartan (dose is sum of agents) • Strengths: 50 mg (24/26mg; white), 100 mg (49/51mg; yellow), 200 mg (97/103mg; pink) o Note: different valsartan salts; Entresto TM valsartan 103mg

2016 RxFiles